Welcome to the
European Biotechnology Network!

The European Biotechnology Network is dedicated to facilitating co-operation between professionals in biotechnology and the life sciences all over Europe.

The non-profit organisation brings research groups, universities, SMEs, large companies and indeed all actors in biotechnology together to build and deliver partnerships.

Read more about our activities here.

Latest Catch

  • Adocia Management: Rémi Soula (Director Business Development and IP), Gérard Soula (CEO), Valérie Danaguezian (CFO), Olivier Soula (Director R&D) © Adocia

    Phase III washout for Adocia

    26.08.2016 Adocia said it would discontinue its diabetic foot ulcer programme after its lead product BioChaperone PDGF disappointed in Phase III. The French company will turn the focus on its earlier-stage products.

    Adocia announced the topline results for its Phase III trial of diabetic foot ulcer treatment BioChaperone PDGF. The product did not meet the primary endpoint in this Phase III trial conducted in India, the Lyon-based company said. CEO Gérard Soula did not hold back his consternation: “We are surprised and disappointed by these topline results, which are inconsistent with previously reported positive Phase 1/2 clinical results.”

    The randomised, double-blind, multicentre, outpatient study enrolled 252 diabetic patients from India with a chronic diabetic foot ulcer. In addition to standard of care, each group of patients was treated every two days for a maximum of 20 weeks with either a placebo spray (saline solution) or a spray containing BC PDGF. However, after this time, BC PDGF did not perform better than the placebo and therefore did not meet the primary endpoint.

    Now, Adocia has decided to stop development in this indication, focusing instead on injectable therapeutics for the treatment of diabetes. “Diabetic foot ulcer has proved an extremely difficult condition to address, as seen in multiple recent late-stage clinical trial failures,” stressed Soula. “The main reason is the lack of uniformity in the standard of care of these types of wounds.”

    The company’s stock price, which had lately reacted favourably to the publication of the financial results, took a hit. Share prices fell by almost 20 percent.

    © european-biotechnology-news.com/um

    The Latest Catch is brought to you by European Biotechnology News

Featured Events

Our Corporate Members are


All events

Membership - Join the Network!

Individual Membership for natural persons is free, while Corporate Membership, for companies, institutions and research groups start from €500 p.a.
Click here to apply for network membership!


European Biotechnology Network AISBL

Rue de la Science 14b
1040 Brussels, Belgium

Tel: +32 27 33 72 37

Funding Hub Strategic Partnership

European Biopharmaceutical Enterprises